AAAAAA
Results:
1-9
|
Results: 9
Authors:
WISEMAN G
WITZIG T
WHITE CA
SOLINGER A
GORDON L
RAUBITSCHEK A
EMMANOUILIDES C
GUTHEIL J
PARKER E
CHINN P
GRILLOLOPEZ A
Citation: G. Wiseman et al., RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) WITH IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 MONOCLONAL-ANTIBODY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 22-22
Authors:
PRIDE MW
SHUEY S
GRILLOLOPEZ A
BRASLAWSKY O
ROSS M
LEGHA SS
ETON O
BUZAID A
IOANNIDES C
MURRAY JL
Citation: Mw. Pride et al., ENHANCEMENT OF CELL-MEDIATED-IMMUNITY IN MELANOMA PATIENTS IMMUNIZED WITH MURINE ANTIIDIOTYPIC MONOCLONAL-ANTIBODIES (MELIMMUNE(R)) THAT MIMIC THE HIGH-MOLECULAR-WEIGHT PROTEOGLYCAN ANTIGEN, Clinical cancer research, 4(10), 1998, pp. 2363-2370
Authors:
ANDERSON DR
GRILLOLOPEZ A
VARNS C
CHAMBERS KS
HANNA N
Citation: Dr. Anderson et al., TARGETED ANTICANCER THERAPY USING RITUXIMAB, A CHIMERIC ANTI-CD20 ANTIBODY (IDEC-C2B8) IN THE TREATMENT OF NON-HODGKINS B-CELL LYMPHOMA, Biochemical Society transactions, 25(2), 1997, pp. 705-708
Authors:
WISEMAN GA
SOLINGER AM
GRILLOLOPEZ A
STABIN M
DUNN WL
WITZIG TE
SPIES S
GORDON L
RAUBITSCHEK A
MARGOLIN K
KARVELIS K
JANAKIRAMAN N
SILVERMAN DH
EMMANOULIDES C
ROYSTON I
CHINN P
PARKER E
CARTER W
WHITE CA
Citation: Ga. Wiseman et al., IDEC-Y2B8 (Y-90 CONJUGATED ANTI-CD20) DOSIMETRY CALCULATED FROM IN-111 ANTI-CD20 IN PATIENTS WITH LOW AND INTERMEDIATE GRADE B-CELL NON-HODGKINS-LYMPHOMA (NHL) EMPHASIS ON BONE-MARROW (BM), Blood, 90(10), 1997, pp. 2273-2273
Authors:
WITZIG T
WISEMAN C
WHITE CA
SOLINGER A
GORDON L
RAUBITSCHEK A
EMMANOULIDES C
ROYSTON I
PARKER E
CHINN P
GRILLOLOPEZ A
Citation: T. Witzig et al., IDEC-Y2B8 (90)YTTRIUM ANTI-CD20 RADIOIMMUNOTHERAPY OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) - INTERIM RESULTS OF A PHASE I II TRIAL/, Blood, 90(10), 1997, pp. 2606-2606
Authors:
KNOX SJ
GORIS ML
TRISLER K
NEGRIN R
DAVIS T
LILES TM
GRILLOLOPEZ A
CHINN P
VARNS C
NING SC
FOWLER S
DEB N
BECKER M
MARQUEZ C
LEVY R
Citation: Sj. Knox et al., YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY OF RECURRENTB-CELL LYMPHOMA, Clinical cancer research, 2(3), 1996, pp. 457-470
Authors:
MALONEY DG
LILES TM
CZERWINSKI DK
WALDICHUK C
ROSENBERG J
GRILLOLOPEZ A
LEVY R
Citation: Dg. Maloney et al., PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA, Blood, 84(8), 1994, pp. 2457-2466
Authors:
BELANGER K
JOLIVET J
MAROUN J
STEWART D
GRILLOLOPEZ A
WHITFIELD L
WAINMAN N
EISENHAUER E
Citation: K. Belanger et al., PHASE-I PHARMACOKINETIC STUDY OF DUP-937, A NEW ANTHRAPYRAZOLE, Investigational new drugs, 11(4), 1993, pp. 301-308
Authors:
MALONEY DG
LILES TM
CZERWINSKI DK
WALDICHUK C
ROSENBERG J
GRILLOLOPEZ A
LEVY R
Citation: Dg. Maloney et al., PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA, Blood, 82(10), 1993, pp. 10000445-10000445
Risultati:
1-9
|